Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition. - Sheppard SE; March ME; Seiler C; Matsuoka LS; Kim SE; Kao C; Rubin AI; Battig MR; Khalek N; Schindewolf E; O'Connor N; Pinto E; et al. (JCI insight, 2023)